Physician
Reliant Medical Group, INC
Reliant Medical Group, INC was paid $101.96M by Medicaid between Jan 2018 and Dec 2024, across 364 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 25% of everything it billed.
33Billing provider infoRELIANT MEDICAL GROUP, INC
WORCESTER, MA 01606
WORCESTER, MA 01606
33aNPI1720017528assigned 07/02/2006
33bProvider typeInternal Medicine Physician
28Total paid$101.96M
24GClaims1,787,969
24DCodes billed364
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Massachusetts
Rank by total paid#1 of 1,270
Median peer was paid$8K
This provider vs. median12,195×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 214,764 | $12.95M | |
| 2019 | 237,445 | $13.03M | |
| 2020 | 217,568 | $13.62M | |
| 2021 | 278,060 | $18.67M | |
| 2022 | 278,565 | $21.60M | |
| 2023 | 271,778 | $13.41M | |
| 2024incomplete | 289,789 | $8.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 25% | 262,624 | 253,459 | $25.59M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 263,381 | 254,447 | $17.47M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.7% | 17,385 | 17,244 | $3.80M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.2% | 74,899 | 38,040 | $3.27M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.1% | 29,782 | 29,775 | $3.20M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.9% | 74,654 | 74,342 | $3.00M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.7% | 23,385 | 23,228 | $2.70M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.4% | 22,925 | 22,922 | $2.44M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.3% | 15,443 | 14,644 | $2.37M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.1% | 50,979 | 23,936 | $2.14M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.1% | 20,572 | 20,189 | $2.10M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.0% | 19,416 | 10,010 | $2.00M |
352 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.9% | 119,472 | $1.91M |
| 90461 | 1.7% | 33,829 | $1.76M | |
| 99204 | Doctor's office visit, new patient (more involved) | 1.6% | 9,857 | $1.64M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.5% | 18,221 | $1.49M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.2% | 18,474 | $1.17M |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 29,763 | $1.08M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 7,903 | $1.04M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 8,856 | $1.00M |
| 76830 | Ultrasound, transvaginal | <1% | 5,447 | $884K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 14,535 | $773K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 12,260 | $725K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 16,548 | $715K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 853 | $710K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,845 | $675K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 18,718 | $655K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,860 | $582K |
| G0008 | Administration of influenza virus vaccine | <1% | 23,484 | $507K |
| 71250 | <1% | 3,184 | $506K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 18,140 | $464K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,813 | $399K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 7,634 | $375K |
| 92015 | Determination of refractive state | <1% | 31,134 | $371K |
| 93000 | <1% | 23,053 | $363K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 4,355 | $331K |
| 76536 | <1% | 2,840 | $328K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 5,110 | $309K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,396 | $305K |
| 97161 | <1% | 3,018 | $304K | |
| 73630 | <1% | 7,688 | $303K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 3,002 | $293K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,335 | $279K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 3,961 | $276K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,036 | $260K |
| 62323 | <1% | 1,442 | $257K | |
| 97803 | <1% | 3,255 | $231K | |
| 76642 | <1% | 2,115 | $228K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 7,666 | $223K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,120 | $218K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 441 | $218K |
| 20610 | <1% | 4,453 | $217K | |
| 71271 | <1% | 1,327 | $213K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,773 | $185K |
| 99173 | <1% | 12,456 | $183K | |
| 11721 | <1% | 7,375 | $172K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,530 | $163K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 27,780 | $152K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,157 | $150K |
| 73130 | <1% | 3,294 | $138K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 925 | $133K |
| 73562 | <1% | 2,503 | $127K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 3,182 | $125K |
| 36415 | Collection of venous blood by venipuncture | <1% | 41,583 | $123K |
| 97802 | <1% | 818 | $119K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 450 | $119K |
| 73030 | <1% | 3,505 | $117K | |
| 92567 | <1% | 4,491 | $110K | |
| 72100 | <1% | 2,859 | $108K | |
| 77002 | <1% | 1,283 | $108K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 644 | $105K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,323 | $103K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 5,405 | $102K |
| 90674 | <1% | 4,990 | $101K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 7,215 | $99K |
| 73610 | <1% | 2,572 | $97K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 8,095 | $97K |
| 64615 | <1% | 563 | $87K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,343 | $81K |
| L3000 | Foot, insert, removable, molded to patient model, 'ucb' type, berkeley shell, each | <1% | 97 | $79K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,170 | $78K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 897 | $78K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 570 | $76K |
| 59510 | <1% | 13 | $76K | |
| 92557 | <1% | 1,454 | $76K | |
| 76818 | <1% | 517 | $76K | |
| 77066 | Tomosynthesis, mammo | <1% | 361 | $74K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 827 | $73K |
| 73560 | <1% | 2,290 | $71K | |
| 76775 | <1% | 1,391 | $70K | |
| 99220 | <1% | 647 | $70K | |
| 73110 | <1% | 1,648 | $69K | |
| 95117 | <1% | 4,624 | $67K | |
| 99223 | Prolong inpt eval add15 m | <1% | 560 | $67K |
| 99205 | Prolong outpt/office vis | <1% | 329 | $64K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,359 | $64K |
| 99188 | <1% | 1,114 | $62K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,233 | $62K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,166 | $62K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,398 | $55K |
| 93015 | <1% | 684 | $53K | |
| 76801 | <1% | 321 | $52K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 306 | $51K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 6,697 | $51K |
| 64493 | <1% | 246 | $48K | |
| 94060 | <1% | 1,613 | $47K | |
| 52000 | <1% | 256 | $47K | |
| 73565 | <1% | 1,411 | $47K | |
| 17110 | <1% | 374 | $46K | |
| 11056 | <1% | 1,340 | $45K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,039 | $44K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 244 | $43K |
| 90686 | <1% | 40,827 | $43K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 112 | $40K |
| 93970 | <1% | 1,933 | $39K | |
| 93971 | <1% | 2,572 | $39K | |
| 64635 | <1% | 114 | $38K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 387 | $37K |
| 90691 | <1% | 349 | $37K | |
| 77065 | Tomosynthesis, mammo | <1% | 244 | $36K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 287 | $36K |
| 92134 | <1% | 854 | $35K | |
| 80061 | Lipid panel | <1% | 2,826 | $34K |
| 90661 | <1% | 2,074 | $34K | |
| 99152 | <1% | 1,950 | $34K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 116 | $33K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 2,491 | $32K |
| 92083 | <1% | 411 | $31K | |
| 77080 | <1% | 1,351 | $31K | |
| 64636 | <1% | 120 | $30K | |
| 99177 | <1% | 3,824 | $30K | |
| 92133 | <1% | 688 | $30K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 699 | $29K |
| 97760 | <1% | 235 | $27K | |
| 90961 | <1% | 287 | $27K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 347 | $27K |
| 86003 | <1% | 2,081 | $26K | |
| 31575 | <1% | 274 | $26K | |
| 97804 | <1% | 394 | $26K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 153 | $25K |
| 73502 | <1% | 746 | $25K | |
| 72141 | <1% | 93 | $25K | |
| 64633 | <1% | 55 | $25K | |
| 31231 | <1% | 125 | $25K | |
| 97165 | <1% | 259 | $25K | |
| 27096 | <1% | 123 | $25K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 64 | $25K |
| 64494 | <1% | 232 | $23K | |
| 64634 | <1% | 55 | $23K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 96 | $22K |
| 64490 | <1% | 122 | $22K | |
| 81025 | <1% | 1,746 | $22K | |
| 90480 | <1% | 373 | $21K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 916 | $20K |
| 83655 | <1% | 1,066 | $20K | |
| 74178 | <1% | 60 | $19K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 59 | $19K |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 1,289 | $17K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 226 | $16K |
| 74018 | <1% | 414 | $15K | |
| 76000 | <1% | 480 | $15K | |
| 51798 | <1% | 1,663 | $15K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,535 | $15K |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 474 | $15K |
| 95886 | <1% | 149 | $15K | |
| 11720 | <1% | 671 | $15K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 363 | $15K |
| 95885 | <1% | 187 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,432 | $13K |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 178 | $13K |
| 90677 | <1% | 1,441 | $12K | |
| 99443 | <1% | 138 | $12K | |
| 82728 | <1% | 607 | $12K | |
| 93224 | <1% | 132 | $12K | |
| 90717 | <1% | 96 | $12K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 73 | $11K |
| 64491 | <1% | 122 | $11K | |
| 99442 | <1% | 211 | $11K | |
| 92136 | <1% | 211 | $11K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 139 | $11K |
| 97162 | <1% | 118 | $10K | |
| 82785 | <1% | 382 | $9K | |
| 85027 | <1% | 1,033 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 437 | $9K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 26 | $9K |
| 94729 | <1% | 1,533 | $9K | |
| 64492 | <1% | 105 | $9K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 599 | $8K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 515 | $8K |
| 99402 | <1% | 241 | $8K | |
| 98968 | <1% | 156 | $8K | |
| 92558 | <1% | 364 | $8K | |
| 99051 | <1% | 506 | $8K | |
| 74183 | <1% | 13 | $8K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 16 | $8K |
| 96127 | <1% | 448 | $7K | |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | <1% | 332 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 93 | $7K |
| 93880 | <1% | 393 | $7K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 590 | $7K |
| 81002 | <1% | 2,203 | $7K | |
| 64495 | <1% | 68 | $7K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 814 | $6K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 38 | $6K |
| 76813 | <1% | 41 | $6K | |
| 11055 | <1% | 268 | $5K | |
| 95912 | <1% | 12 | $5K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 41 | $5K |
| 90962 | <1% | 51 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 305 | $5K |
| 72050 | <1% | 95 | $5K | |
| 87631 | <1% | 27 | $5K | |
| 99201 | <1% | 99 | $5K | |
| 69210 | <1% | 241 | $5K | |
| 99350 | Prolong home eval add 15m | <1% | 39 | $5K |
| 92552 | <1% | 161 | $5K | |
| 94726 | <1% | 589 | $5K | |
| 93975 | <1% | 12 | $5K | |
| 97035 | <1% | 294 | $4K | |
| 94010 | <1% | 551 | $4K | |
| 93296 | <1% | 403 | $4K | |
| 77062 | <1% | 15 | $4K | |
| 92587 | <1% | 74 | $4K | |
| 92556 | <1% | 113 | $4K | |
| 97167 | <1% | 37 | $4K | |
| 73221 | <1% | 13 | $4K | |
| 57288 | <1% | 12 | $4K | |
| 93294 | <1% | 284 | $3K | |
| 92002 | <1% | 38 | $3K | |
| 92551 | <1% | 174 | $3K | |
| 81003 | <1% | 1,282 | $3K | |
| 99384 | <1% | 26 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 25 | $3K |
| 73564 | <1% | 56 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 135 | $3K |
| 73080 | <1% | 76 | $3K | |
| 77061 | <1% | 28 | $2K | |
| 99226 | <1% | 36 | $2K | |
| 0012A | <1% | 85 | $2K | |
| 90694 | <1% | 67 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 308 | $2K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 20 | $2K |
| 99401 | <1% | 101 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 137 | $2K |
| 29540 | <1% | 166 | $2K | |
| 94727 | <1% | 231 | $2K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 124 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 76 | $2K |
| 99217 | <1% | 37 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 15 | $2K |
| 0011A | <1% | 145 | $2K | |
| 95910 | <1% | 17 | $2K | |
| 98940 | <1% | 243 | $2K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 18 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 38 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 38 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 63 | $2K |
| 84439 | <1% | 196 | $2K | |
| 64405 | <1% | 16 | $2K | |
| 86780 | <1% | 90 | $2K | |
| 99441 | <1% | 43 | $2K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 27 | $2K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 88 | $2K |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 12 | $1K |
| 91320 | <1% | 16 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $1K |
| 99310 | Prolong nursin fac eval 15m | <1% | 44 | $1K |
| 0074A | <1% | 21 | $1K | |
| 87206 | <1% | 172 | $1K | |
| 96381 | <1% | 50 | $1K | |
| 90715 | <1% | 28 | $1K | |
| 72070 | <1% | 34 | $1K | |
| 99307 | <1% | 179 | $1K | |
| 97166 | <1% | 12 | $1K | |
| 90750 | <1% | 14 | $1K | |
| 99221 | <1% | 26 | $1K | |
| 92555 | <1% | 52 | $1K | |
| 93295 | <1% | 58 | $1K | |
| 86140 | <1% | 219 | $1K | |
| 82570 | <1% | 303 | $1K | |
| V5266 | Battery for use in hearing device | <1% | 16 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 90 | $948.68 |
| 85018 | <1% | 272 | $926.81 | |
| 11100 | <1% | 12 | $916.43 | |
| 85651 | <1% | 249 | $872.15 | |
| ATP14 | <1% | 389 | $849.74 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 47 | $816.64 |
| 59025 | Fetal non-stress test | <1% | 15 | $741.31 |
| 72040 | <1% | 16 | $714.96 | |
| 0112A | <1% | 12 | $712.80 | |
| 87081 | <1% | 76 | $699.38 | |
| ATP17 | <1% | 209 | $691.11 | |
| 84450 | <1% | 92 | $685.26 | |
| 92579 | <1% | 12 | $669.99 | |
| 82962 | <1% | 298 | $666.34 | |
| 86008 | <1% | 26 | $660.12 | |
| 29580 | <1% | 33 | $603.65 | |
| 84460 | <1% | 78 | $602.19 | |
| 84702 | <1% | 37 | $593.52 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 391 | $584.09 |
| 20552 | <1% | 15 | $581.94 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 17 | $558.82 |
| 87660 | <1% | 24 | $539.38 | |
| 20550 | <1% | 13 | $512.33 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $454.21 |
| 73140 | <1% | 16 | $445.75 | |
| 82947 | <1% | 77 | $442.30 | |
| 95115 | <1% | 39 | $422.29 | |
| 90662 | <1% | 78 | $381.93 | |
| 90651 | <1% | 893 | $321.90 | |
| 87480 | <1% | 12 | $312.29 | |
| 90619 | <1% | 75 | $311.47 | |
| 87510 | <1% | 12 | $306.87 | |
| 90653 | <1% | 28 | $306.81 | |
| ATP11 | <1% | 100 | $300.63 | |
| 99493 | <1% | 63 | $291.84 | |
| ATP08 | <1% | 229 | $279.36 | |
| 82043 | <1% | 59 | $250.72 | |
| 86803 | <1% | 12 | $237.30 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 33 | $233.82 |
| 99397 | <1% | 14 | $233.49 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 32 | $219.93 |
| 88720 | <1% | 39 | $205.77 | |
| 84703 | <1% | 25 | $202.98 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 12 | $175.40 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 63 | $166.75 |
| ATP03 | <1% | 46 | $164.40 | |
| 93018 | <1% | 12 | $130.69 | |
| 93923 | <1% | 12 | $125.79 | |
| 99494 | <1% | 34 | $98.12 | |
| 82950 | <1% | 12 | $88.70 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 98 | $83.23 |
| S0028 | Injection, famotidine, 20 mg | <1% | 15 | $66.95 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 153 | $61.16 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 43 | $51.01 |
| 90744 | <1% | 1,596 | $39.94 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13 | $30.92 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 46 | $5.64 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 75 | $0.14 |
| 90685 | 0% | 1,173 | $0.00 | |
| 1159F | 0% | 41,091 | $0.00 | |
| 1160F | 0% | 41,036 | $0.00 | |
| 90633 | 0% | 2,217 | $0.00 | |
| 90734 | 0% | 146 | $0.00 | |
| 90670 | 0% | 9,593 | $0.00 | |
| 90671 | 0% | 618 | $0.00 | |
| 91321 | 0% | 207 | $0.00 | |
| 91311 | 0% | 69 | $0.00 | |
| 90710 | 0% | 65 | $0.00 | |
| 90707 | 0% | 73 | $0.00 | |
| 90672 | 0% | 27 | $0.00 | |
| 90697 | 0% | 2,088 | $0.00 | |
| 90680 | 0% | 4,977 | $0.00 | |
| 90716 | 0% | 90 | $0.00 | |
| 90698 | 0% | 6,918 | $0.00 | |
| G1015 | Clinical decision support mechanism reliant medical group, as defined by the medicare appropriate use criteria program | 0% | 1,734 | $0.00 |
| 91301 | 0% | 84 | $0.00 | |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | 0% | 120 | $0.00 |
| 96380 | 0% | 71 | $0.00 | |
| 94761 | 0% | 12 | $0.00 | |
| 91307 | 0% | 20 | $0.00 | |
| 90696 | 0% | 24 | $0.00 | |
| 90381 | 0% | 47 | $0.00 | |
| 99385 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHILLING, THAD (CMO)